BIIB is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about BIIB. We will be studying the movement so you can make the best decision as an investor. The stock has moved $11.57 from yesterday’s closing price of $395.37. The high for today is $414.78 and the low for today is $391.005. Let’s learn more about the company and then get into the forecast.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
As an investor, you can get an idea of where the stock is trending by the forecast. In this case, BIIB is projected to have a price of $411.57 in one year which is a 101.137759866319% change. They have a strong market cap of $43079.73 and a very bright future ahead of them. Make sure to subscribe to our newsletter to never miss an update!